Importantly, the anti-tumor effects of ACBP/DBI neutralization are not solely due to its hepatoprotective properties, as they persist in mouse models of HCC driven by oncogenes (e.g., β-catenin and MYC) or orthotopic injection of syngeneic liver cancer cells into immunocompetent hosts. Here, MYC is linked to neoplasm.